Streetbeat News

Stock Prices

VTGN

VistaGen Therapeutics announced that its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of fasedienol has met the primary and secondary endpoints. This positive news has led to an increase in the company's share price.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 1:05 pm

SVFD

Shares of Save Foods (SVFD) are trading higher on abnormally-high volume, despite no company-specific news to justify the price action.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 1:03 pm

LUV

Over the past 3 months, 16 analysts have published their opinion on Southwest Airlines (NYSE:LUV) stock. The average price target is $40.38, implying an upside from the current price of $32.73. This represents a 11.81% decrease from the previous average price target of $45.79.

Portfolio Pulse from Benzinga Insights

August 07, 2023 | 1:00 pm

SQ

Over the past 3 months, 16 analysts have published their opinion on Block (NYSE:SQ) stock. The average price target is $85.0, implying an upside from the current price of $63.52. This represents a 1.36% decrease from the previous average price target of $86.17.

Portfolio Pulse from Benzinga Insights

August 07, 2023 | 1:00 pm

PNR

In the last quarter, Pentair (NYSE:PNR) received mostly bullish ratings from analysts. The average 12-month price target for the company, according to 10 analysts, is $76.5, with a high of $88.00 and a low of $58.00. This average price target has increased by 15.04% over the past month.

Portfolio Pulse from Benzinga Insights

August 07, 2023 | 1:00 pm

CI

In the last quarter, Cigna Group (NYSE:CI) received 7 analyst ratings, with 5 being bullish, 2 somewhat bullish, and none being bearish or indifferent. The company has an average 12-month price target of $343.71, a decrease of 1.01% from the previous average price target of $347.20.

Portfolio Pulse from Benzinga Insights

August 07, 2023 | 1:00 pm

SEMR

SEMrush Hldgs (SEMR) has received mostly bullish ratings from analysts in the last quarter, with an average 12-month price target of $11.92, an increase of 8.36% over the past month. The ratings are based on the company's predicted future earnings and the predictability of its revenue streams.

Portfolio Pulse from Benzinga Insights

August 07, 2023 | 1:00 pm

DKNG

DraftKings Inc (NASDAQ:DKNG) reported Q2 results that exceeded analysts' estimates, leading to a rise in its shares. The company also raised its full-year guidance. CEO Jason Robins highlighted the company's ongoing migration to its proprietary technology platform and increased customer acquisition at lower costs. DraftKings expects to be profitable by Q4 2023 and fiscal 2024. The company will host an investor day in November to discuss the outlook for fiscal 2024 and future projections beyond 2023.

Portfolio Pulse from Chris Katje

August 07, 2023 | 12:58 pm

QSI

Quantum-Si's shares are trading lower following the company's worse-than-expected Q2 sales results.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 12:58 pm

BIIB

SAGE

The FDA has approved Sage Therapeutics Inc (SAGE) and Biogen Inc's (BIIB) Zurzuvae (zuranolone) 50 mg for adults with postpartum depression (PPD). The drug is the first oral, once-daily, 14-day treatment for PPD and is expected to be commercially available in Q4 2023. However, the FDA rejected the drug for the treatment of adults with major depressive disorder (MDD), stating that additional studies will be needed. The stocks of both companies might fall due to the smaller patient population for PPD.

Portfolio Pulse from Vandana Singh

August 07, 2023 | 12:57 pm